SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has climbed to a fresh 52-week high amid anticipation of its Q3 earnings report and continued optimism around BRIUMVIs growth. Traders debate whether the rally reflects earnings expectations and business momentum or buyout and short-covering speculation; a potential acquisition remains unconfirmed.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is under pressure amid approaching midterms, with traders focusing on reports that Trump canceled campaign rallies and on expectations of Democratic gains that could bring greater scrutiny of his administration. Bearish posts dominate, while some bulls argue the selloff could reverse after the election.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

A sharp pullback in ALAB has traders focused on whether it can hold key chart support ahead of earnings, with the report and guidance viewed as a potential catalyst. Bulls call the drop an opportunity amid continued AI data-center demand, while bears point to the stocks rich valuation and concerns about a broader AI-trade slowdown.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

American Airlines results and weaker outlook have focused attention on soaring jet-fuel costs, which are squeezing margins despite strong revenue and travel demand. Traders are divided between concerns about losses and the airlines heavy debt burden, and hopes that lower fuel prices and premium demand could support a recovery.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis Corp 

Federal cannabis rescheduling is the dominant topic, with traders focused on procedural delays in the DEA process and uncertainty around when a Schedule III decision could arrive. Some see the delays and resulting weakness as an overreaction and a potential buying opportunity, while others are frustrated that the catalyst remains uncertain and has not supported the shares.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

Rising concern about AI-enabled cyberattacks is fueling discussion of SentinelOnes cybersecurity opportunity, while traders also emphasize its lower valuation than peers and speculate about a potential takeover. Those bullish themes are offset by worries about growth, recent financing-related dilution, and weakness across cybersecurity stocks; no acquisition is confirmed.

MaxLinear, Inc. engages in the provision of communications systems-on-chip (SoC) solutions used in broadband, mobile and wireline infrastructure, data center, and industrial and multi-market applications. Its products include cable broadband modems and gateways, wireline connectivity devices, radio frequency transceivers, fiber-optic modules, video set-top boxes and gateways, hybrid analog and digital televisions, direct broadcast satellite outdoor and indoor units, and power management and interface products. The company was founded by Kimihiko Imura, Curtis C. Ling, and Kishore V. Seendripu on September 25, 2003 and is headquartered in Carlsbad, CA.

MaxLinear Inc

MaxLinears strong quarterly results and higher outlook, driven by accelerating AI data-center optics demand, are the main focus. Traders are divided as the shares sell off despite the upbeat report, with some buying the dip while others point to volatility and weak cash generation as risks.

Tidal Trust II - Defiance Daily Target 2x Long MSTR ETF

Defiance Daily Target 2x Long MSTR ETF

MSTXs sharp drop is drawing dip-buying and rebound speculation, while bearish traders warn that further weakness in Bitcoin or Strategy (MSTR) could deepen losses. The debate also centers on the funds 2x daily leverage and volatility decay, which can erode returns when held through choppy markets.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors approaching FDA decision on deramiocel for Duchenne muscular dystrophy is driving attention, with traders focused on the November 22 target date, the revised upper-limb data, and recent commercial job postings. Some see FDA flexibility and INOs approval as encouraging signals, while others caution that hiring is not proof of approval and cite the prior AdCom concerns and efficacy debate.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo shares are under pressure after MaxLinear outlined plans to compete for a share of the 1.6T cable market that Credo currently dominates. Traders debate whether the threat is meaningful given its timeline and expanding demand, while broader AI-sector weakness and insider selling add to bearish sentiment; others view the decline as an overreaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Compass Therapeutics’ FDA Setback Raises Concerns On Wall Street — H.C. Wainwright Calls Tovecimig Filing Strategy ‘Risky’ 

Equity

Several analysts slashed their price targets on Compass Therapeutics after the FDA requested an additional trial for its cancer drug.

This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Analysts downgraded Accelerant, Autoliv, Compass Therapeutics, Wave Life Sciences and PG&E; price targets for CMPX and PCG were cut.read more...

CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug — Wedbush Sees Another 19% Downside  

Compass said on Tuesday that the FDA recommended a trial showing a survival benefit before the company files a biologics license application for tovecimig in previously treated advanced biliary tract cancer. 


Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug

Compass Therapeutics shares plunge after FDA seeks a survival-benefit trial before tovecimig's FDA marketing application.read more...

 CMPX Stock Crashes To Over 2-Year Lows — Why FDA Wants Another Cancer Therapy Trial Before Key Marketing Filing

The FDA wants Compass to conduct a trial showing Tovecimig can improve overall survival in patients with previously treated, advanced biliary tract cancer.


A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire NEW YORK, June 30, 2026 Issued on behalf of GT Biopharma, Inc.GT...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Canaccord Genuity Group Lowers Compass Therapeutics (NASDAQ:CMPX) Price Target to $7.00

Canaccord Genuity Group dropped their price objective on shares of Compass Therapeutics from $13.00 to $7.00 and set a "buy" rating for the company in a report on Tuesday...

Citizens Jmp Reiterates Market Outperform Rating for Compass Therapeutics (NASDAQ:CMPX)

Citizens Jmp restated a "market outperform" rating and issued a $10.00 price target on shares of Compass Therapeutics in a research note on Tuesday...

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Compass Therapeutics Inc

Neutral Sentiment

<ul class="summary-bullets"><li>H.C. Wainwright cut CMPX target to $12 from $24, according to The Fly.</li><li>Wedbush downgraded Compass and slashed its target to $1 from $5, while Guggenheim halved its target to $4.</li><li>Compass plans to submit a BLA in the first quarter of 2027.</li></ul><p>Shares of Compass Therapeutics (CMPX) fell more than 6% on Wednesday, heading for a third straight decline as analysts cut their price targets after a regulatory setback for the biotech’s lead cancer drug, Tovecimig.</p><p><a href="https://stocktwits.com/symbol/CMPX">CMPX stock</a> is also heading for its 10th decline in 12 sessions.</p><h2 class="st-heading-2">Analyst Flags Higher Approval Risk</h2><p>H.C. Wainwright cut its price target to $12 from $24, while keeping a ‘Buy’ rating, according to TheFly. The firm said it continues to believe Tovecimig works but called Compass’ plan to seek approval without another trial “risky,” noting that no confirmatory study is currently enrolling.</p><p>On Tuesday, the Food and Drug Administration (FDA) <a href="https://stocktwits.com/news-articles/markets/equity/cmpx-stock-crashes-to-over-2-year-lows-why-fda-wants-another-cancer-therapy-trial-before-key-marketing-filing/cZMPqcmRBew">recommended</a> another trial showing that Tovecimig improves overall survival in previously treated advanced biliary tract cancer before Compass submits its Biologics License Application (BLA).</p><p>Compass said it disagrees that another trial is necessary and plans to submit a BLA in the first quarter of 2027.</p><h2 class="st-heading-2">Wedbush Slashes Target To $1 From $5</h2><p>Wedbush downgraded Compass to ‘Neutral’ from ‘Outperform’ and cut its target to $1 from $5, saying the FDA’s recommendation significantly complicates the regulatory path. The stock is currently trading at $1.2.</p><p>Guggenheim halved its target to $4 from $8, maintaining a ‘Buy’ rating, and called the FDA development “disappointing.” The firm now sees a potential U.S. launch in 2028 instead of 2027.</p><p>The company ended June with roughly $180 million in cash and marketable securities, expected to fund operations into 2028.</p><h2 class="st-heading-2">Retail’s Take On CMPX</h2><p>Retail sentiment for CMPX on Stocktwits turned ‘extremely bullish’ from ‘bullish’ over the past 24 hours, amid ‘extremely high’ message volumes.</p><p>The stock has fallen more than 76% so far this year.</p><p><strong>Also read: </strong><a href="https://stocktwits.com/news-articles/markets/equity/immunovant-pulls-plug-on-lupus-program-after-study-misses-primary-goal-imvt-stock-heads-for-over-3-month-lows/cZMEuqwRBJh"><strong>Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal — IMVT Stock Heads For Over 3-Month Lows</strong></a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

In this photo illustration, the Compass Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.7865
Prev Close	$0.7562
Open	$0.756
Dividend Yield	0.00%
50-Day Moving Average	$1.46
Beta	1.60
Avg. Volume	4.67M
PE Ratio	-1.95

52-Week High	$6.88
52-Week Low	$0.73
Market Capitalization	$141.64M
EPS (Annual)	-$0.4216
Price to Book	0.85
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

CMPX Fundamentals